

- COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies. *Vaccines (Basel)* 11 (2023): 662.
35. Lopes LA, Agrawal DK. Thromboembolism in the Complications of Long COVID-19. *Cardiol Cardiovasc Med* 7 (2023): 123-128.
 36. Yazdani AN, Abdi A, Velpuri P, Patel P, DeMarco N, Agrawal DK, et al. A Review of Hematological Complications and Treatment in COVID-19. *Hematol Rep* 15 (2023): 562-577.
 37. Babulal GM, Torres VL, Acosta D, Agüero C, Aguilar-Navarro S, Amariglio R, et al. The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. *EClinicalMedicine* 35 (2021): 100848.
 38. S J, Sreedharan S. Analysing the Covid-19 Cases in Kerala: a Visual Exploratory Data Analysis Approach. *SN Compr Clin Med* 2 (2020): 1337-1348.
 39. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. *SN Compr Clin Med* 2 (2020): 1069-1076.
 40. Alyammahi SK, Abdin SM, Alhamad DW, Elgendy SM, Altell AT, Omar HA. The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities. *Infect Genet Evol* 87 (2021): 104647.
 41. Loosen SH, Jensen BO, Tanislav C, Luedde T, Roderburg C, Kostev K. Obesity and lipid metabolism disorders determine the risk for development of long COVID syndrome: a cross-sectional study from 50,402 COVID-19 patients. *Infection* 50 (2022): 1165-1170.
 42. Bozkurt B, Das SR, Addison D, Gupta A, Jneid H, Khan SS, et al. 2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. *Circ Cardiovasc Qual Outcomes* 15 (2022): e000111.
 43. Bozkurt B, Hershberger RE, Butler J, Grady KL, Heidenreich PA, Isler ML, et al. 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). *Circ Cardiovasc Qual Outcomes* 14 (2021): e000102.
 44. Kulpa DA, Lawani M, Cooper A, Peretz Y, Ahlers J, Sékaly RP. PD-1 coinhibitory signals: the link between pathogenesis and protection. *Semin Immunol* 25 (2013): 219-27.
 45. Fisher MC, Fazzari MJ, Hanna DB, Patel VV, Felsen UR, Alahiri E, et al. Brief Report: Acute Kidney Injury in People Living with HIV Hospitalized with Coronavirus Disease 2019: Clinical Characteristics and Outcomes. *J Acquir Immune Defic Syndr* 87 (2021): 1167-1172.
 46. Lobato TB, Gennari-Felipe M, Pauferro JRB, Correa IS, Santos BF, Dias BB, et al. Leukocyte metabolism in obese type 2 diabetic individuals associated with COVID-19 severity. *Front Microbiol* 13 (2022): 1037469.
 47. Jang S, Hong W, Moon Y. Obesity-compromised immunity in post-COVID-19 condition: a critical control point of chronicity. *Front Immunol* 15 (2024): 1433531.
 48. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. *World J Gastroenterol* 21 (2015): 8787-803.
 49. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J* 474 (2017): 1823-1836.
 50. Mitrea L, Nemeş SA, Szabo K, Teleky BE, Vodnar DC. Guts Imbalance Imbalances the Brain: A Review of Gut Microbiota Association With Neurological and Psychiatric Disorders. *Front Med (Lausanne)*. 2022 Mar 31;9:813204. doi: 10.3389/fmed.2022.813204. PMID: 35433746; PMCID: PMC9009523.
 51. Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. *Gut* 71 (2022): 544-552.
 52. Zhou Y, Zhang J, Zhang D, Ma WL, Wang X. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. *J Microbiol* 59 (2021): 941-948.
 53. Malinowska AM, Majcher M, Hooiveld GJ, Przydatek H, Szaban M, Kurowiecka A, et al. Experimental Capacity of Human Fecal Microbiota to Degrade Fiber and Produce Short-Chain Fatty Acids Is Associated with Diet Quality and Anthropometric Parameters. *J Nutr* 153 (2023): 2827-2841.
 54. Peng X, Li S, Luo J, Wu X, Liu L. Effects of dietary fibers and their mixtures on short chain fatty acids and microbiota in mice guts. *Food Funct* 4 (2013): 932-8.
 55. De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Stora A, Laghi L, et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. *Gut* 65 (2016): 1812-1821.

56. Tomova A, Bukovsky I, Rembert E, Yonas W, Alwarith J, Barnard ND, et al. The Effects of Vegetarian and Vegan Diets on Gut Microbiota. *Front Nutr* 6 (2019): 47.
57. Galena AE, Chai J, Zhang J, Bednarzyk M, Perez D, Ochriotor JD, et al. The effects of fermented vegetable consumption on the composition of the intestinal microbiota and levels of inflammatory markers in women: A pilot and feasibility study. *PLoS One* 17 (2022): e0275275.
58. Borrello K, Lim U, Park SY, Monroe KR, Maskarinec G, Boushey CJ, et al. Dietary Intake Mediates Ethnic Differences in Gut Microbial Composition. *Nutrients* 14 (2022): 660.
59. Banu N, Panikar SS, Leal LR, Leal AR. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. *Life Sci* 256 (2020): 117905.
60. Mkoma GF, Agyemang C, Benfield T, Rostila M, Cederström A, Petersen JH, et al. Risk of long COVID and associated symptoms after acute SARS-COV-2 infection in ethnic minorities: A nationwide register-linked cohort study in Denmark. *PLoS Med* 21 (2024): e1004280.
61. O'Laughlin KN, Klabbbers RE, Ebna Mannan I, Gentile NL, Geyer RE, Zheng Z, et al. INSPIRE Group. Ethnic and racial differences in self-reported symptoms, health status, activity level, and missed work at 3 and 6 months following SARS-CoV-2 infection. *Front Public Health* 11 (2024): 1324636.
62. Karaca-Mandic P, Georgiou A, Sen S. Assessment of COVID-19 Hospitalizations by Race/Ethnicity in 12 States. *JAMA Intern Med* 181 (2021): 131-134.
63. Acosta AM, Garg S, Pham H, Whitaker M, Anglin O, O'Halloran A, et al. Racial and Ethnic Disparities in Rates of COVID-19-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death in the United States From March 2020 to February 2021. *JAMA Netw Open* 4 (2021): e2130479.
64. Zuo T, Wu X, Wen W, Lan P. Gut Microbiome Alterations in COVID-19. *Genomics Proteomics Bioinformatics* 19 (2021): 679-688.
65. Li H, Wen J, Zhang X, Dai Z, Liu M, Zhang H, Zhang N, Lei R, Luo P, Zhang J. Large-scale genetic correlation studies explore the causal relationship and potential mechanism between gut microbiota and COVID-19-associated risks. *BMC Microbiol* 24 (2024): 292.
66. Kropp C, Le Corf K, Relizani K, Tambosco K, Martinez C, Chain F, et al. The Keystone commensal bacterium *Christensenella minuta* DSM 22607 displays anti-inflammatory properties both in vitro and in vivo. *Sci Rep* 11 (2021): 11494.
67. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. *Am J Physiol Heart Circ Physiol* 318 (2020): H1084-H1090.
68. Gavzy SJ, Kensiski A, Lee ZL, Mongodin EF, Ma B, Bromberg JS. Bifidobacterium mechanisms of immune modulation and tolerance. *Gut Microbes* 15 (2023): 2291164.
69. Zhang Z, Lv J, Pan L, Zhang Y. Roles and applications of probiotic *Lactobacillus* strains. *Appl Microbiol Biotechnol* 102 (2018): 8135-8143.
70. Ang QY, Alba DL, Upadhyay V, Bisanz JE, Cai J, Lee HL, et al. The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health. *Elife* 10 (2021): e70349.
71. Ecklu-Mensah G, Choo-Kang C, Maseng MG, Donato S, Bovet P, et al. Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: the METS-microbiome study. *Nat Commun* 14 (2023): 5160.
72. Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? *Am J Physiol Heart Circ Physiol* 310 (2016): H137-52.
73. Song L, Ji W, Cao X. Integrated analysis of gut microbiome and its metabolites in ACE2-knockout and ACE2-overexpressed mice. *Front Cell Infect Microbiol* 14 (2024): 1404678.
74. Penninger JM, Grant MB, Sung JY. The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection. *Gastroenterology* 160 (2021): 39-46.
75. Yu Z, Yang Z, Wang Y, Zhou F, Li S, Li C, Li L, Zhang W, Li X. Recent advance of ACE2 and microbiota dysfunction in COVID-19 pathogenesis. *Heliyon* 7 (2021): e07548.
76. Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B, et al. Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19. *EBioMedicine* 83 (2022): 104195.
77. Nagashima S, Dutra AA, Arantes MP, Zeni RC, Klein CK, de Oliveira FC, et al. COVID-19 and Lung Mast Cells: The Kallikrein-Kinin Activation Pathway. *Int J Mol Sci* 23 (2022): 1714.
78. Tabassum A, Iqbal MS, Sultan S, Alhuthali RA, Alshubaili DI, Sayyam RS, Abyad LM, Qasem AH, Arbaeen AF. Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19. *Mediators Inflamm* 8 (2022): 7423537.

79. Ramasamy S, Subbian S. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. *Clin Microbiol Rev* 34 (2021): e00299-20.
80. Guo ZY, Tang YQ, Zhang ZB, Liu J, Zhuang YX, Li T. COVID-19: from immune response to clinical intervention. *Precis Clin Med* 7 (2024): pbae015.
81. Sharma RK, Li J, Krishnan S, Richards EM, Raizada MK, Mohandas R. Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. *Clin Sci (Lond)* 135 (2021): 1-17.
82. Nishimura N, Kaji K, Kitagawa K, Sawada Y, Furukawa M, Ozutsumi T, et al. Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. *Int J Mol Sci* 22 (2021): 6921.
83. Kosek E. The concept of nociplastic pain-where to from here? *Pain* 165 (2024): S50-S57.
84. Khoja O, Silva-Passadouro B, Cristescu E, McEwan K, Doherty D, O'Connell F, et al. Clinical Characterization of New-Onset Chronic Musculoskeletal Pain in Long COVID: A Cross-Sectional Study. *J Pain Res* 17 (2024): 2531-2550.
85. Kassem A, Henning P, Kindlund B, Lindholm C, Lerner UH. TLR5, a novel mediator of innate immunity-induced osteoclastogenesis and bone loss. *FASEB J* 29 (2015): 4449-60.
86. Guss JD, Horsfield MW, Fontenele FF, Sandoval TN, Luna M, Apoorva F, et al. Alterations to the Gut Microbiome Impair Bone Strength and Tissue Material Properties. *J Bone Miner Res* 32 (2017): 1343-1353.
87. Zhang X, Chen K, Chen X, Kourkoumelis N, Li G, Wang B, et al. Integrative Analysis of Genomics and Transcriptome Data to Identify Regulation Networks in Female Osteoporosis. *Front Genet* 11 (2020): 600097.
88. Papageorgiou M, Biver E. Interactions of the microbiome with pharmacological and non-pharmacological approaches for the management of ageing-related musculoskeletal diseases. *Ther Adv Musculoskelet Dis* 13 (2021): 1759720X211009018.
89. Li W, Lai K, Chopra N, Zheng Z, Das A, Diwan AD. Gut-disc axis: A cause of intervertebral disc degeneration and low back pain? *Eur Spine J* 31 (2022): 917-925.
90. Dekker Nitert M, Mousa A, Barrett HL, Naderpoor N, de Courten B. Altered Gut Microbiota Composition Is Associated with Back Pain in Overweight and Obese Individuals. *Front Endocrinol (Lausanne)* 11 (2020): 605.
91. Rajasekaran S, Soundararajan DCR, Tangavel C, Muthurajan R, Sri Vijay Anand KS, Matchado MS, et al. Human intervertebral discs harbour a unique microbiome and dysbiosis determines health and disease. *Eur Spine J* 29 (2020): 1621-1640.
92. Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. *Nat Rev Rheumatol* 10 (2014): 44-56.
93. Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. *Psychosom Med* 70 (2008): 890-7.
94. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. TLC Study Group. Symptoms, complications and management of long COVID: a review. *J R Soc Med* 114 (2021): 428-442.
95. Junco B, Samano Martin Del Campo D, Karakeshishyan V, Bass D, Sobczak E, Swafford E, et al. Long-term brain fog and cognitive impairment in previously hospitalized COVID-19 patients. *PLoS One* 19 (2024): e0309102.
96. Alenina N, Bader M. ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models. *Neurochem Res* 44 (2019): 1323-1329.
97. Lindskog C, Méar L, Virhammar J, Fällmar D, Kumlien E, Hesselager G, et al. Protein Expression Profile of ACE2 in the Normal and COVID-19-Affected Human Brain. *J Proteome Res* 21 (2022): 2137-2145.
98. Yong SJ. Persistent Brainstem Dysfunction in Long-COVID: A Hypothesis. *ACS Chem Neurosci* 12 (2021): 573-580.
99. Podell K, Gifford K, Bougakov D, Goldberg E. Neuropsychological assessment in traumatic brain injury. *Psychiatr Clin North Am* 33 (2010): 855-76.
100. Kumar A, Pareek V, Prasoon P, Faiq MA, Kumar P, Kumari C, et al. Possible routes of SARS-CoV-2 invasion in brain: In context of neurological symptoms in COVID-19 patients. *J Neurosci Res* 98 (2020): 2376-2383.
101. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. *Neurobiol Dis* 16 (2004): 1-13.
102. Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T. Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. *Neuroscience* 171 (2010): 852-8.
103. Theoharides TC, Kempuraj D. Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and

- Mast Cells in the Pathogenesis of Neuro-COVID. *Cells* 12 (2023): 688.
104. Sajdel-Sulkowska EM. Neuropsychiatric Ramifications of COVID-19: Short-Chain Fatty Acid Deficiency and Disturbance of Microbiota-Gut-Brain Axis Signaling. *Biomed Res Int* (2021): 7880448.
105. Garrett RE, Palacio CH, Bar-Or D. Long COVID: Is there a kidney link? *Front Med (Lausanne)* 10 (2023): 1138644.
106. Soleimani M. Acute Kidney Injury in SARS-CoV-2 Infection: Direct Effect of Virus on Kidney Proximal Tubule Cells. *Int J Mol Sci* 21 (2020): 3275.
107. Zhang Y, Zhao Y, Wang J, Zheng X, Xu D, Lv J, Yang L. Long-term renal outcomes of patients with COVID-19: a meta-analysis of observational studies. *J Nephrol* 36 (2023): 2441-2456.
108. Cei F, Chiarugi L, Brancati S, Montini MS, Dolenti S, Di Stefano D, et al. Early reduction of estimated Glomerular Filtration Rate (eGFR) predicts poor outcome in acutely ill hospitalized COVID-19 patients firstly admitted to medical regular wards (eGFR-COV19 study). *Biomed Pharmacother* 153 (2022): 113454.
109. Gupta R, Woo K, Yi JA. Epidemiology of end-stage kidney disease. *Semin Vasc Surg* 34 (2021): 71-78.
110. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney Int* 98 (2020): 219-227.
111. Zadeh FH, Wilson DR, Agrawal DK. Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies. *Arch Microbiol Immunol* 7 (2023): 36-61.
112. Mahmoodpoor F, Rahbar Saadat Y, Barzegari A, Ardalan M, Zununi Vahed S. The impact of gut microbiota on kidney function and pathogenesis. *Biomed Pharmacother* 93 (2017): 412-419.
113. Maciel RAP, Cunha RS, Busato V, Franco CRC, Gregório PC, Dolenga CJR, et al. Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions. *Toxins (Basel)* 10 (2018): 404.
114. Kudose S, Batal I, Santoriello D, Xu K, Barasch J, Peleg Y, et al. Kidney Biopsy Findings in Patients with COVID-19. *J Am Soc Nephrol* 31 (2020): 1959-1968.
115. Wais T, Hasan M, Rai V, Agrawal DK. Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics. *Expert Rev Clin Immunol* 18 (2022): 947-960.
116. Qu L, Chen C, Yin T, Fang Q, Hong Z, Zhou R, et al. ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. *Int J Mol Sci* 22 (2021): 11483.
117. Pinto BGG, Oliveira AER, Singh Y, Jimenez L, Gonçalves ANA, Ogava RLT, et al. ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19. *J Infect Dis* 222 (2020): 556-563.
118. Hartwell BL, Melo MB, Xiao P, Lemnios AA, Li N, Chang JYH, et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. *Sci Transl Med* 14 (2022): eabn1413.
119. Luo A, Leach ST, Barres R, Hesson LB, Grimm MC, Simar D. The Microbiota and Epigenetic Regulation of T Helper 17/Regulatory T Cells: In Search of a Balanced Immune System. *Front Immunol* 8 (2017): 417.
120. Wang J, Li F, Wei H, Lian ZX, Sun R, Tian Z. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. *J Exp Med* 211 (2014): 2397-410.
121. Vestad B, Ueland T, Lerum TV, Dahl TB, Holm K, Barratt-Due A, et al. NOR-Solidarity study group. Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations. *J Intern Med* 291 (2022): 801-812.
122. Jakubec P, Fišerová K, Genzor S, Kolář M. Pulmonary Complications after COVID-19. *Life (Basel)* 12 (2022): 357.
123. Chilazi M, Duffy EY, Thakkar A, Michos ED. COVID and Cardiovascular Disease: What We Know in 2021. *Curr Atheroscler Rep* 23 (2021): 37.
124. Becker RC. Anticipating the long-term cardiovascular effects of COVID-19. *J Thromb Thrombolysis* 50 (2020): 512-524.
125. Saeed S, Mancina G. Arterial stiffness and COVID-19: A bidirectional cause-effect relationship. *J Clin Hypertens (Greenwich)* 23 (2021): 1099-1103.
126. Sha'ari NI, Ismail A, Abdul Aziz AF, Suddin LS, Azzeri A, Sk Abd Razak R, et al. Cardiovascular diseases as risk factors of post-COVID syndrome: a systematic review. *BMC Public Health* 24 (2024): 1846.
127. Pływaczewska-Jakubowska M, Chudzik M, Babicki M, Kapusta J, Jankowski P. Lifestyle, course of COVID-19, and risk of Long-COVID in non-hospitalized patients. *Front Med (Lausanne)* 9 (2022): 1036556.
128. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an Association Between COVID-19

- Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. *Clin Infect Dis* 71 (2020): 870-874.
129. Li M, van Esch BCAM, Henricks PAJ, Folkerts G, Garssen J. The Anti-inflammatory Effects of Short Chain Fatty Acids on Lipopolysaccharide- or Tumor Necrosis Factor α -Stimulated Endothelial Cells via Activation of GPR41/43 and Inhibition of HDACs. *Front Pharmacol* 9 (2018): 533.
 130. Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. *Gut Microbes* 13 (2021): 1-24.
 131. Zhang D, Zhou Y, Ma Y, Chen P, Tang J, Yang B, et al. Gut Microbiota Dysbiosis Correlates with Long COVID-19 at One-Year After Discharge. *J Korean Med Sci* 38 (2023): e120.
 132. Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. *Gut* 71 (2022): 544-552.
 133. Romano KA, Vivas EI, Amador-Noguez D, Rey FE. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. *mBio* 6 (2015): e02481.
 134. Rath S, Heidrich B, Pieper DH, Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. *Microbiome* 5 (2017): 54.
 135. Basting CM, Langat R, Broedlow CA, Guerrero CR, Bold TD, Bailey M, et al. SARS-CoV-2 infection is associated with intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized patients. *Microbiol Spectr* 12 (2024): e0068024.
 136. Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. *Gastroenterology* 159 (2020): 944-955.e8.
 137. Yang HT, Jiang ZH, Yang Y, Wu TT, Zheng YY, Ma YT, et al. Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe. *Cell Commun Signal* 22 (2024): 54.
 138. Luo Y, Chang G, Yu G, Lin Y, Zhang Q, Wang Z, et al. Unveiling the negative association of Faecalibacterium prausnitzii with ischemic stroke severity, impaired prognosis and pro-inflammatory markers. *Heliyon* 10 (2024): e26651.
 139. Lymberopoulos E, Gentili GI, Budhdeo S, Sharma N. COVID-19 severity is associated with population-level gut microbiome variations. *Front Cell Infect Microbiol* 12 (2022): 963338.
 140. Liu Y, Chan MTV, Chan FKL, Wu WKK, Ng SC, Zhang L. Lower gut abundance of Eubacterium rectale is linked to COVID-19 mortality. *Front Cell Infect Microbiol* 13 (2023): 1249069.